Antitumor activity of new morpholino anthracyclines.
- 1 January 1988
- journal article
- research article
- Published by Japan Antibiotics Research Association in The Journal of Antibiotics
- Vol. 41 (4) , 548-553
- https://doi.org/10.7164/antibiotics.41.548
Abstract
Antitumor activity of 3''-deamino-3''-morpholino anthracyclines were examined. Morpholino derivatives of 13-deoxocarminomycins, MX2 (1), MX (2) and MY5 (3) shown in Fig. 1, administered iv showed increase in life span (ILS) values over 110% against ip-inoculated P388 leukemia. The ranges of effective doses of these compounds were broader than those of their parent drugs. The morpholino derivatives of doxorubicin and carminomycin, however, were not so effective as their parent drugs. Among these compounds, MX2 administered orally showed nearly the same effects as those obtained by iv administration against P388 leukemia. MX2 administered iv showed 89% ILS against intracerebrally-inoculated L1210 leukemia. The highly lipophilic nature of MX2 could contribute partly to achieving chemotherapeutic responses against intracerebrally-inoculated tumors or by oral administration.This publication has 4 references indexed in Scilit:
- Intensely potent anthracycline antibiotic oxaunomycin produced by a blocked mutant of the daunorubicin-producing microorganism.The Journal of Antibiotics, 1986
- 13-Deoxycarminomycin, a New Biosynthetic AnthracyclineJournal of Natural Products, 1985
- Intensely potent morpholinyl anthracyclinesJournal of Medicinal Chemistry, 1984
- New anthracycline glycosides: 4-O-demethyl-11-deoxydoxorubicin and analogues from Streptomyces peucetius var. aureus.The Journal of Antibiotics, 1982